ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

NVAX Company Profile and Key Details

NASDAQ : NVAX

Novavax, Inc.

$6.24

0.64+11.43%

Open: 4:00 PM

61.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

NVAX Stock Price Chart

Stock Price Today

Novavax, Inc. (NVAX) stock surged +11.43%, trading at $6.24 on NASDAQ, up from the previous close of $5.60. The stock opened at $5.40, fluctuating between $5.33 and $6.32 in the recent session.

Stock Snapshot

5.6

Prev. Close

5.4

Open

Market Cap

160.84M

Number of Shares

5.33

Day Low

6.315

Day High

-5.07

P/E Ratio

91.13%

Free Float in %

-1.23

EPS (TTM)

-5.8

Book Value

-6.25

Cash Flow per Share

9.13M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 04, 2025	5.40	6.32	5.33	6.24	9.19M
Apr 03, 2025	5.58	5.83	5.35	5.60	6.19M
Apr 02, 2025	5.90	6.23	5.70	5.98	10.43M
Apr 01, 2025	6.41	6.43	6.00	6.00	5.35M
Mar 31, 2025	6.49	6.59	6.28	6.41	4.61M
Mar 28, 2025	7.24	7.29	6.93	7.00	2.78M
Mar 27, 2025	7.36	7.42	7.24	7.26	2.6M
Mar 26, 2025	7.56	7.57	7.25	7.39	2.9M
Mar 25, 2025	7.68	7.72	7.48	7.56	2.27M
Mar 24, 2025	7.62	7.81	7.58	7.69	2.34M
Mar 21, 2025	7.58	7.66	7.47	7.60	3.44M
Mar 20, 2025	7.81	7.91	7.65	7.72	2.57M
Mar 19, 2025	7.91	8.05	7.82	7.91	2.25M
Mar 18, 2025	8.33	8.36	7.81	7.95	4.21M
Mar 17, 2025	8.03	8.51	8.01	8.38	3.97M
Mar 14, 2025	8.30	8.52	7.96	7.99	5.04M
Mar 13, 2025	8.03	8.50	7.97	8.17	3.01M
Mar 12, 2025	7.88	8.19	7.86	8.10	2.83M
Mar 11, 2025	8.01	8.33	7.66	7.92	3.2M
Mar 10, 2025	8.14	8.47	8.07	8.18	3.73M

Contact Details

Gaithersburg, MD 20878

United States

Website: https://www.novavax.comContact: 240 268 2000

About Company

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Frequently Asked Questions

What is the current Novavax, Inc. (NVAX) stock price?

Novavax, Inc. (NASDAQ: NVAX) stock price is $6.24 in the last trading session. During the trading session, NVAX stock reached the peak price of $6.32 while $5.33 was the lowest point it dropped to. The percentage change in NVAX stock occurred in the recent session was 11.43% while the dollar amount for the price change in NVAX stock was $0.64.

NVAX's industry and sector of operation?

The NASDAQ listed NVAX is part of Biotechnology industry that operates in the broader Healthcare sector. Novavax, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NVAX?

Mr. Biegie Lee
Senior Vice President & Chief Information Officer
Mr. Troy Morgan Esq., J.D.
Senior Vice President & Chief Compliance Officer
Ms. Erika S. Trahan
Associate Director of Investor & PR
Mr. Stanley Charles Erck
Advisor
Mr. John A. Herrmann III
Executive Vice President, Chief Legal Officer & Corporation Sec.
Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer
Dr. Gregory M. Glenn
Pres of R&D
Dr. Gale E. Smith
Senior Vice President of Discovery & Pre-Clinical Research and Chief Scientist
Dr. Gregory M. Glenn M.D.
Pres of R&D
Mr. John A. Herrmann III, J.D.
Executive Vice President & Chief Legal Officer
Mr. John Joseph Trizzino B.S., M.B.A.
Executive Vice President, Chief Commercial Officer & Chief Bus. Officer
Dr. Filip Dubovsky FAAP, M.D., M.P.H.
Pres of R&D
Ms. Jill Hoyt SPHR
Executive Vice President & Chief HR Officer
Ms. Silvia Taylor M.B.A., MBA
Executive Vice President and Chief Corporation Affairs & Advocacy Officer
Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer

How NVAX did perform over past 52-week?

NVAX's closing price is 63.78% higher than its 52-week low of $3.81 where as its distance from 52-week high of $23.86 is -73.85%.

How many employees does NVAX have?

Number of NVAX employees currently stands at 952.

Link for NVAX official website?

Official Website of NVAX is: https://www.novavax.com

How do I contact NVAX?

NVAX could be contacted at phone 240 268 2000 and can also be accessed through its website. NVAX operates from 21 Firstfield Road, Gaithersburg, MD 20878, United States.

How many shares of NVAX are traded daily?

NVAX stock volume for the day was 9.13M shares. The average number of NVAX shares traded daily for last 3 months was 4.49M.

What is the market cap of NVAX currently?

The market value of NVAX currently stands at $1.00B with its latest stock price at $6.24 and 160.84M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	952
Beta	2.91
Sales or Revenue	$983.71M
5Y Sales Change%	1.977%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology